You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: April 14, 2025

PTAB Cases from Eton Pharmaceuticals, Inc.

✉ Email this page to a colleague

« Back to Dashboard

Patent Trial and Appeal Board Cases for Petitioner: Eton Pharmaceuticals, Inc.

+ Get email alerts for changes to this table

Show entries

Subscribe to access the full database, or Try for Free
Patent	Petitioner	Status	Filing Date	Accorded Filing Date	Patent Owner	Trial Type	Trial Number	Decision Date	Inventor	Document Download

10,653,719	Eton Pharmaceuticals, Inc.	⤷ Try for Free	2020-09-21	09-21-2020		Post-grant review	⤷ Try for Free	04-23-2021		⤷ Try for Free
10,478,453	Eton Pharmaceuticals, Inc.	⤷ Try for Free	2020-05-19	05-19-2020		Post-grant review	⤷ Try for Free	11-18-2020		⤷ Try for Free
>Patent	>Petitioner	>Status	>Filing Date	>Accorded Filing Date	>Patent Owner	>Trial Type	>Trial Number	>Decision Date	>Inventor	>Document Download

Showing 1 to 2 of 2 entries

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.